Stage‑dependent changes of β2‑adrenergic receptor signaling in right ventricular remodeling in monocrotaline‑induced pulmonary arterial hypertension

Sun,Fengjiao; Lu,Zhiqiang; Zhang,Yidan; Geng,Shihan; Xu,Mengxi; Xu,Liman; Huang,Yingying; Zhuang,Pengwei; Zhang,Yanjun

doi:10.3892/ijmm.2018.3449

Stage‑dependent changes of β2‑adrenergic receptor signaling in right ventricular remodeling in monocrotaline‑induced pulmonary arterial hypertension

Authors:
- Fengjiao Sun
- Zhiqiang Lu
- Yidan Zhang
- Shihan Geng
- Mengxi Xu
- Liman Xu
- Yingying Huang
- Pengwei Zhuang
- Yanjun Zhang
View Affiliations

Affiliations: Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, P.R. China, Department of Pharmacology, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, P.R. China
Published online on: February 1, 2018 https://doi.org/10.3892/ijmm.2018.3449
Pages: 2493-2504
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Right ventricular (RV) remodeling coupled with extensive apoptosis in response to unrestrained biomechanical stress may lead to RV failure (RVF), which is the immediate cause of death in the majority of patients with pulmonary arterial hypertension (PAH). Overexpression of β2‑adrenergic receptor (β2‑AR) signaling has been reported to induce myocardiotoxicity in patients with left heart failure. However, the role of β2‑AR signaling in the pathophysiology of PAH development has remained elusive. To address this issue, the present study investigated the changes in cardiopulmonary function and structure, as well as the expression of regulators of fibrosis and apoptosis in RVF following monocrotaline (MCT; 60 mg/kg, i.p.)‑induced PAH in rats. Cardiopulmonary function and structure, remodeling and apoptosis, as well as G protein‑coupled receptor (GPCR) and β2‑AR signaling, were documented over a period of 6 weeks. In the early stages, elevated pulmonary arterial pressure, pulmonary lesions, RV hypertrophy, evidence of left ventricular (LV) hyperfunction and accelerated heart rate were observed in animals with MCT‑induced PAH. The levels of angiotensin II receptor type 1b (Agtr1b), Agtr2 and Agt were markedly upregulated and the expression of β2‑AR phospho‑Ser(355,356) steadily decreased in the right heart. As the disease progressed, LV dysfunction was observed, as evidenced by decreased LV systolic pressure and increased LV end‑diastolic pressure, which was accompanied by a sustained increase in circulating brain natriuretic peptide levels. Of note, increased levels of cardiomyocyte apoptosis and concomitant RV remodeling, including hypertrophy, dilatation, inflammation and fibrosis, were observed, despite the enhanced RV contractility. Furthermore, alterations in GPCR signaling and activation in β2‑AR‑Gs‑protein kinase A/Ca2+/calmodulin‑dependent kinase II signaling were observed in the late stages of PAH. These results suggested that treatment with MCT results in adaptive and maladaptive RV remodeling and apoptosis during the progression of PAH, which is accompanied by distinct changes in the β2‑AR signaling. Therefore, these results enable researchers to better understand of pathophysiology of MCT‑induced PAH, as well as to determine the effects of novel therapies.

View Figures

View References

1	Ryan JJ, Huston J, Kutty S, Hatton ND, Bowman L, Tian L, Herr JE, Johri AM and Archer SL: Right ventricular adaptation and failure in pulmonary arterial hypertension. Can J Cardiol. 31:391–406. 2015. View Article : Google Scholar : PubMed/NCBI
2	Vonk-Noordegraaf A, Haddad F, Chin KM, Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ, Provencher S, et al: Right heart adaptation to pulmonary arterial hypertension: Physiology and pathobiology. J Am Coll Cardiol. 62(Suppl 25): D22–D33. 2013. View Article : Google Scholar : PubMed/NCBI
3	Hardziyenka M, Campian ME, Reesink HJ, Surie S, Bouma BJ, Groenink M, Klemens CA, Beekman L, Remme CA, Bresser P and Tan HL: Right ventricular failure following chronic pressure overload is associated with reduction in left ventricular mass: Evidence for atrophic remodeling. J Am Coll Cardiol. 57:921–928. 2011. View Article : Google Scholar : PubMed/NCBI
4	Hsia HH and Haddad F: Pulmonary hypertension: A stage for ventricular interdependence? J Am Coll Cardiol. 59:2203–2205. 2012. View Article : Google Scholar : PubMed/NCBI
5	Lee-Chiong TL Jr and Matthay RA: Pulmonary hypertension and cor pulmonale in COPD. Semin Respir Crit Care Med. 24:263–272. 2003. View Article : Google Scholar
6	Montani D, Gunther S, Dorfmuller P, Perros F, Girerd B, Garcia G, Jaïs X, Savale L, Artaud-Macari E, Price LC, et al: Pulmonary arterial hypertension. Orphanet J Rare Dis. 8:972013. View Article : Google Scholar : PubMed/NCBI
7	Rubin LJ: The beta-adrenergic receptor in pulmonary arterial hypertension: A novel therapeutic target. J Am Coll Cardiol. 65:681–683. 2015. View Article : Google Scholar : PubMed/NCBI
8	Mendes-Ferreira P, Santos-Ribeiro D, Adão R, Maia-Rocha C, Mendes-Ferreira M, Sousa-Mendes C, Leite-Moreira AF and Brás-Silva C: Distinct right ventricle remodeling in response to pressure overload in the rat. Am J Physiol Hear Circ Physiol. 311:H85–H95. 2016. View Article : Google Scholar
9	Rain S, Handoko ML, Trip P, Gan CT, Westerhof N, Stienen GJ, Paulus WJ, Ottenheijm CA, Marcus JT, Dorfmüller P, et al: Right ventricular diastolic impairment in patients with pulmonary arterial hypertension. Circulation. 128:2025. 2013. View Article : Google Scholar
10	Campian ME, Verberne HJ, Hardziyenka M, de Bruin K, Selwaness M, van den Hoff MJ, Ruijter JM, van Eck-Smit BL, de Bakker JM and Tan HL: Serial noninvasive assessment of apoptosis during right ventricular disease progression in rats. J Nucl Med. 50:1371–1377. 2009. View Article : Google Scholar : PubMed/NCBI
11	Paffett ML, Hesterman J, Candelaria G, Lucas S, Anderson T, Irwin D, Hoppin J, Norenberg J and Campen MJ: Longitudinal in vivo SPECT/CT imaging reveals morphological changes and cardiopulmonary apoptosis in a rodent model of pulmonary arterial hypertension. PLoS One. 7:e409102012. View Article : Google Scholar : PubMed/NCBI
12	Wang Y, Ouyang M, Wang Q and Jian Z: MicroRNA-142-3p inhibits hypoxia/reoxygenation-induced apoptosis and fibrosis of cardiomyocytes by targeting high mobility group box 1. Int J Mol Med. 38:1377–1386. 2016. View Article : Google Scholar : PubMed/NCBI
13	Bisognano JD, Weinberger HD, Bohlmeyer TJ, Pende A, Raynolds MV, Sastravaha A, Roden R, Asano K, Blaxall BC, Wu SC, et al: Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol. 32:817–830. 2000. View Article : Google Scholar : PubMed/NCBI
14	Iwai-Kanai E, Hasegawa K, Araki M, Kakita T, Morimoto T and Sasayama S: alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. Circulation. 100:305–311. 1999. View Article : Google Scholar : PubMed/NCBI
15	Zhang X, Szeto C, Gao E, Tang M, Jin J, Fu Q, Makarewich C, Ai X, Li Y, Tang A, et al: Cardiotoxic and cardioprotective features of chronic β-adrenergic signaling. Circ Res. 112:498–509. 2013. View Article : Google Scholar
16	Lymperopoulos A, Rengo G and Koch WJ: Adrenergic nervous system in heart failure: Pathophysiology and therapy. Circ Res. 113:739–753. 2013. View Article : Google Scholar : PubMed/NCBI
17	Woo AY, Song Y, Xiao RP and Zhu W: Biased β2-adrenoceptor signalling in heart failure: Pathophysiology and drug discovery. Br J Pharmacol. 172:5444–5456. 2015. View Article : Google Scholar
18	Daaka Y, Luttrell LM and Lefkowitz RJ: Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature. 390:88–91. 1997. View Article : Google Scholar : PubMed/NCBI
19	Rengo G, Lymperopoulos A, Leosco D and Koch WJ: GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol. 50:785–792. 2011. View Article : Google Scholar
20	Salazar NC, Vallejos X, Siryk A, Rengo G, Cannavo A, Liccardo D, De Lucia C, Gao E, Leosco D, Koch WJ and Lymperopoulos A: GRK2 blockade with βARKct is essential for cardiac β2-adrenergic receptor signaling towards increased contractility. Cell Commun Signal. 11:642013. View Article : Google Scholar
21	Zhu W, Petrashevskaya N, Ren S, Zhao A, Chakir K, Gao E, Chuprun JK, Wang Y, Talan M, Dorn GW II, et al: Gi-biased β2AR signaling links GRK2 upregulation to heart failure. Circ Res. 110:265–274. 2012. View Article : Google Scholar
22	Nikolaev VO, Moshkov A, Lyon AR, Miragoli M, Novak P, Paur H, Lohse MJ, Korchev YE, Harding SE and Gorelik J: Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science. 327:1653–1657. 2010. View Article : Google Scholar : PubMed/NCBI
23	Lang D, Holzem K, Kang C, Xiao M, Hwang HJ, Ewald GA, Yamada KA and Efimov IR: Arrhythmogenic remodeling of β2 versus β1 adrenergic signaling in the human failing heart. Circ Arrhythmia Electrophysiol. 8:409–419. 2015. View Article : Google Scholar
24	Wang Y, Yuan J, Qian Z, Zhang X, Chen Y, Hou X and Zou J: β2 adrenergic receptor activation governs cardiac repolarization and arrhythmogenesis in a guinea pig model of heart failure. Sci Rep. 5:76812015. View Article : Google Scholar
25	Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN and Voelkel NF: Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med. 182:652–660. 2010. View Article : Google Scholar : PubMed/NCBI
26	Perros F, Ranchoux B, Izikki M, Bentebbal S, Happé C, Antigny F, Jourdon P, Dorfmüller P, Lecerf F, Fadel E, et al: Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. J Am Coll Cardiol. 65:668–680. 2015. View Article : Google Scholar : PubMed/NCBI
27	Ishikawa M, Sato N, Asai K, Takano T and Mizuno K: Effects of a pure alpha/beta-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats. Circ J. 73:2337–2341. 2009. View Article : Google Scholar : PubMed/NCBI
28	Okumura K, Kato H, Honjo O, Breitling S, Kuebler WM, Sun M and Friedberg MK: Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension. J Mol Med. 93:663–674. 2015. View Article : Google Scholar : PubMed/NCBI
29	Zhuang P, Huang Y, Lu Z, Yang Z, Xu L, Sun F, Zhang Y and Duan J: cAMP-PKA-CaMKII signaling pathway is involved in aggravated cardiotoxicity during fuzi and beimu combination treatment of experimental pulmonary hypertension. Sci Rep. 6:349032016. View Article : Google Scholar : PubMed/NCBI
30	Deten A, Millar H and Zimmer HG: Catheterization of pulmonary artery in rats with an ultraminiature catheter pressure transducer. Am J Physiol Circ Physiol. 285:H2212–H2217. 2003. View Article : Google Scholar
31	Schmittgen TD, Lee EJ, Jiang J, Sarkar A, Yang L, Elton TS and Chen C: Real-time PCR quantification of precursor and mature microRNA. Methods. 44:31–38. 2008. View Article : Google Scholar
32	Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu L, Mahuvakar VR, Andersen MR, et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
33	Zhuang P, Zhang Y, Cui G, Bian Y, Zhang M, Zhang J, Liu Y, Yang X, Isaiah AO, Lin Y and Jiang Y: Direct stimulation of adult neural stem/progenitor cells in vitro and neurogenesis in vivo by salvianolic acid B. PLoS One. 7:e356362012. View Article : Google Scholar : PubMed/NCBI
34	Hessel MH, Steendijk P, den Adel B, Schutte CI and van der Laarse A: Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Hear Circ Physiol. 291:H2424–H2430. 2006. View Article : Google Scholar
35	Werchan PM, Summer WR, Gerdes AM and McDonough KH: Right ventricular performance after monocrotaline-induced pulmonary hypertension. Am J Physiol Circ Physiol. 256:H1328–H1336. 1989. View Article : Google Scholar
36	Kuehne T, Yilmaz S, Steendijk P, Moore P, Groenink M, Saaed M, Weber O, Higgins CB, Ewert P, Fleck E, et al: Magnetic resonance imaging analysis of right ventricular pressure-volume loops in vivo validation and clinical application in patients with pulmonary hypertension. Circulation. 110:2010–2016. 2004. View Article : Google Scholar : PubMed/NCBI
37	Ameri P, Bertero E, Meliota G, Cheli M, Canepa M, Brunelli C and Balbi M: Neurohormonal activation and pharmacological inhibition in pulmonary arterial hypertension and related right ventricular failure. Hear Fail Rev. 21:539–547. 2016. View Article : Google Scholar
38	Usui S, Yao A, Hatano M, Kohmoto O, Takahashi T, Nagai R and Kinugawa K: Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension. Circ J. 70:1208–1215. 2006. View Article : Google Scholar : PubMed/NCBI
39	Giannakoulas G, Mouratoglou SA, Gatzoulis MA and Karvounis H: Blood biomarkers and their potential role in pulmonary arterial hypertension associated with congenital heart disease. A systematic review. Int J Cardiol. 174:618–623. 2014. View Article : Google Scholar : PubMed/NCBI
40	Luchner A, Hengstenberg C, Löwel H, Riegger GA, Schunkert H and Holmer S: Effect of compensated renal dysfunction on approved heart failure markers direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension. 46:118–123. 2005. View Article : Google Scholar : PubMed/NCBI
41	Grailer JJ, Haggadone MD, Sarma JV, Zetoune FS and Ward PA: Induction of M2 regulatory macrophages through the β2-adrenergic receptor with protection during endotoxemia and acute lung injury. J Innate Immun. 6:607–618. 2014. View Article : Google Scholar :
42	Burke DL, Frid MG, Kunrath CL, Karoor V, Anwar A, Wagner BD, Strassheim D and Stenmark KR: Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol. 297:L238–L250. 2009. View Article : Google Scholar : PubMed/NCBI
43	Baker AJ: Adrenergic signaling in heart failure: A balance of toxic and protective effects. Pflugers Arch. 466:1139–1150. 2014. View Article : Google Scholar : PubMed/NCBI
44	Fajardo G, Zhao M, Urashima T, Farahani S, Hu DQ, Reddy S and Bernstein D: Deletion of the β2-adrenergic receptor prevents the development of cardiomyopathy in mice. J Mol Cell Cardiol. 63:155–164. 2013. View Article : Google Scholar : PubMed/NCBI
45	Rybin VO, Pak E, Alcott S and Steinberg SF: Developmental changes in beta2-adrenergic receptor signaling in ventricular myocytes: The role of Gi proteins and caveolae microdomains. Mol Pharmacol. 63:1338–1348. 2003. View Article : Google Scholar : PubMed/NCBI
46	So PP, Davies RA, Chandy G, Stewart D, Beanlands RS, Haddad H, Pugliese C and Mielniczuk LM: Usefulness of beta-blocker therapy and outcomes in patients with pulmonary arterial hypertension. Am J Cardiol. 109:1504–1509. 2012. View Article : Google Scholar : PubMed/NCBI
47	Thenappan T, Roy SS, Duval S, Glassner-Kolmin C and Gomberg-Maitland M: β-blocker therapy is not associated with adverse outcomes in patients with pulmonary arterial hypertension: A propensity score analysis. Circ Hear Fail. 7:903–910. 2014. View Article : Google Scholar
48	Bandyopadhyay D, Bajaj NS, Zein J, Minai OA and Dweik RA: Outcomes of β-blocker use in pulmonary arterial hypertension: A propensity-matched analysis. Eur Respir J. 46:750–760. 2015. View Article : Google Scholar : PubMed/NCBI
49	Chatterjee S, Udell JA, Sardar P, Lichstein E and Ryan JJ: Comparable benefit of β-blocker therapy in heart failure across regions of the world: Meta-analysis of randomized clinical trials. Can J Cardiol. 30:898–903. 2014. View Article : Google Scholar : PubMed/NCBI
50	Yang Z, Lu ZQ, Zhang YJ, Li YB, Wang ZY, Zhang YL, Zhuang PW and Bai G: Looking for agonists of β2 adrenergic receptor from Fuzi and Chuanwu by virtual screening and dual-luciferase reporter assay. J Asian Nat Prod Res. 18:550–561. 2016. View Article : Google Scholar